Clinical Trial Detail

NCT ID NCT01716806
Title A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Seattle Genetics, Inc.
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Nivolumab

Brentuximab vedotin + Bendamustine

Brentuximab vedotin + Dacarbazine

Brentuximab vedotin

Age Groups: senior adult

No variant requirements are available.